Sentences with phrase «lower macroeconomic growth»

The AEO2015 cases with the largest differences in cumulative emissions from the Reference case are two cases that consider higher or lower macroeconomic growth.

Not exact matches

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Steady - above trend global growth is supportive of low - vol regimes, yet we see the potential for greater macroeconomic uncertainty — and volatility.

In the developed economies in particular, where low growth rates driven by macroeconomic issues, as well as the threat of increase regulation and taxation on sugared drinks and alcoholic beverage, means beverage manufacturers rely on partners to provide the innovations to facilitate growth.

The strategies for achieving these broad macroeconomic objectives include the following: • Promoting inclusive growth without compromising fiscal consolidation; • Anchoring fiscal policy on reducing the fiscal deficit to low and sustainable levels, sufficient to reduce the overall public debt burden; • Strengthening the inflation targeting regime and pursuing complementary monetary policy to promote monetary discipline; and • Pursuing complementary external sector policies to ensure exchange rate stability and favourable current account balance.

A deal that sees all major emitters cutting greenhouse gases will be key to driving the needed global investment in low - carbon growth, the commission argues, calling it a «powerful macroeconomic policy instrument» that will send clear signals to businesses and investors.

Ian Shepherdson, chief economist at Pantheon Macroeconomics, noted that the growth in spending is being funded by a fall in the saving rate, which is set to drop to 2.9 percent — its lowest level in a decade — in the fourth quarter of 2017.